行情

ITCI

ITCI

INTRA CELLULAR
NASDAQ

实时行情|Nasdaq Last Sale

15.82
+0.29
+1.87%
盘后: 15.82 0 0.00% 16:09 03/27 EDT
开盘
15.13
昨收
15.53
最高
16.48
最低
14.75
成交量
90.55万
成交额
--
52周最高
43.56
52周最低
6.75
市值
10.46亿
市盈率(TTM)
-5.9103
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ITCI价格均价为46.00,最高价位70.00,最低价为35.00。

EPS

ITCI 新闻

更多
  • 大众CEO迪斯:每周损失20亿欧元 除中国市场外无收入
  • 21世纪经济报道 · 1小时前
  • 美国医用防护物资短缺 特朗普:波音、福特也要造呼吸机!
  • 环球网 · 2小时前
  • 朝“虑”夕改 特朗普称没必要对纽约等三州进行隔离
  • 央视 · 2小时前
  • 澳大利亚专家反思:应该更早对美国实施边境禁入
  • 央视 · 3小时前

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

ITCI 简况

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
展开

微牛提供Intra-Cellular Therapies Inc(NASDAQ-ITCI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ITCI股票新闻,以帮助您做出投资决策。